RPGR rs121918231: Understanding the Genetic Variant
The genetic variant rs121918231 is a rare alteration located in the RPGR gene on the human X chromosome. It represents a pathogenic loss-of-function mutation associated with X-linked retinitis pigmentosa, a hereditary condition marked by early and progressive rod-cone photoreceptor degeneration. Because it is inherited on the X chromosome, the associated vision loss typically manifests most severely in hemizygous males.
What each genotype means
Typical risk profile
You carry two copies of the common reference allele at this locus in the RPGR gene. Research shows this baseline genotype does not confer the severe, early rod-cone photoreceptor degeneration seen with pathogenic truncating variants. This result is consistent with standard population risk for RPGR-related retinal dystrophies.
Carried by virtually all individuals across global populations, with an estimated prevalence exceeding 99.99%.
X-linked carrier status
You carry one copy of the pathogenic nonsense variant at this position on chromosome X. Because RPGR-related retinitis pigmentosa follows an X-linked pattern, female carriers frequently show variable outcomes ranging from absence of symptoms to mild tapetoretinal sheen or later-onset photoreceptor dysfunction due to random X-inactivation. Research classifies this nonsense change as high-risk, though clinical presentations in heterozygous individuals can vary markedly.
Extremely rare across all ancestries, observed at an overall gnomAD allele frequency of less than 0.001%.
Severe retinal dystrophy risk
This genotype represents carrying the pathogenic nonsense mutation on all tested X chromosomes, typical of hemizygous affected males or very rare homozygous females. In published clinical studies, this premature termination codon leads to loss of functional RPGR protein, strongly associated with severe, early-onset X-linked retinitis pigmentosa marked by progressive rod-cone degeneration. Phenotypic severity is typically high, often presenting with night blindness and visual field constriction beginning in childhood.
Extremely rare worldwide, with documented population allele frequencies in gnomAD well under 0.001%.
Genomic Location and Variant Characteristics
The variant rs121918231 is situated within the retinitis pigmentosa GTPase regulator (RPGR) gene on the short arm of the X chromosome at cytogenetic band Xp11.4. In human genetics catalogs like dbSNP and ClinVar, this variant is classified as a pathogenic nonsense change. Nonsense mutations introduce a premature termination codon into the protein-coding sequence of the messenger RNA, leading to either nonsense-mediated mRNA decay or the production of a truncated, non-functional protein. Because the variant resides on a sex chromosome, genetic manifestations depend heavily on biological sex: males possess only a single X chromosome (hemizygosity) and express the affected allele directly, whereas females carry two X chromosomes and may be heterozygous carriers.
Function of the RPGR Gene in Vision
The RPGR gene encodes a protein that is critical for the long-term survival and function of photoreceptor cells within the retina. Photoreceptors—classified into rods for night and peripheral vision, and cones for central and color vision—rely on specialized structures known as connecting cilia. RPGR localizes predominantly to these connecting cilia, where it facilitates protein trafficking and metabolic transport between the inner and outer segments of retinal cells. Disruption of RPGR function compromises this essential molecular transport mechanism. Over time, the inability to move proteins effectively through the cilia leads to toxic intracellular accumulation, cellular stress, and the accelerated degeneration of rod and cone photoreceptors.
Clinical Associations and Strength of Evidence
Pathogenic variants in RPGR are the most common cause of X-linked retinitis pigmentosa (XLRP), accounting for an estimated 70 to 90 percent of XLRP cases worldwide. Retinitis pigmentosa typically begins in childhood or adolescence with nyctalopia (night blindness), followed by progressive loss of the peripheral visual field, often culminating in severe visual impairment. Although catalog evidence for this specific variant is labeled as limited due to its extreme rarity in the general population, loss-of-function alleles in RPGR are clinically well-established drivers of rod-cone dystrophy. Heterozygous females may remain asymptomatic or exhibit variable, milder symptoms due to skewed X-chromosome inactivation.
Population Frequency and Demographics
According to large-scale genomic reference resources such as the Genome Aggregation Database (gnomAD), the rs121918231 variant is exceptionally rare across all global ancestries, with an overall allele frequency under 0.00001 (less than 1 in 100,000 individuals). Because pathogenic mutations leading to severe, early-onset retinal degeneration are subject to strong negative selection, they rarely reach high frequencies in general population cohorts. In clinical cohorts of individuals affected by inherited retinal dystrophies, RPGR variants are frequently identified, yet specific single nucleotide changes like rs121918231 are typically found only in isolated families or unique pedigree analyses.
Navigating Genetic Results Responsibly
Encountering a variant such as rs121918231 on a raw DNA file or clinical report requires careful medical context. Consumer-grade genetic screening is not designed to diagnose or rule out inherited retinal diseases, and raw data may occasionally contain false-positive findings or misannotations. Individuals with concerns regarding visual symptoms, nyctalopia, or a family history of retinitis pigmentosa should pursue dedicated evaluation with an ophthalmologist or a medical geneticist. Accredited clinical genetic tests use rigorous Sanger validation or high-depth next-generation sequencing to confirm findings and guide clinical care, surveillance, and family planning.
How common is this variant?
The rs121918231 variant is extraordinarily rare globally, with an estimated allele frequency in large population databases such as gnomAD of less than 0.00001. Most individuals in every surveyed ancestry carry the standard reference allele.
Frequently asked questions
What health conditions are associated with rs121918231?
The rs121918231 variant is associated with X-linked retinitis pigmentosa, a genetic eye condition characterized by progressive degeneration of the retina's rod and cone photoreceptors. Affected individuals typically experience night blindness during childhood followed by progressive peripheral vision loss.
Why does this RPGR variant affect males and females differently?
Because the RPGR gene is located on the X chromosome, males have only one copy and will experience significant retinal degeneration if that copy harbors a pathogenic variant. Females have two X chromosomes, meaning an intact second copy often provides partial protection, though variable retinal symptoms can still develop.
Can commercial consumer DNA tests reliably identify rs121918231?
Most consumer genotyping microarrays are optimized for common variants and have elevated error rates when detecting very rare single-nucleotide variants. Any finding involving rs121918231 from consumer raw data must be confirmed in an accredited clinical laboratory before drawing medical conclusions.
What steps should someone take if this variant appears on a test report?
If this variant is flagged on a genetic report, it is best to consult with an ophthalmologist or a board-certified genetic counselor. A medical specialist can evaluate visual function, review personal and family history, and order confirmatory diagnostic testing if clinically indicated.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918231?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29